Petrova Natalia N, Serazetdinova Valeria S
Saint Petersburg State University.
Consort Psychiatr. 2020 Dec 4;1(2):53-62. doi: 10.17650/2712-7672-2020-1-2-53-62.
This article discusses case reports of treatment with paliperidone palmitate in comparison with data from recent publications. Second-generation long-acting injectable antipsychotics have been shown to provide better control of psychiatric manifestations, reduce the severity of negative symptoms, improve social functioning and quality of life of patients and relatives, and reduce the burden of disease for both the healthcare system and the caregivers. The case reports presented in this article demonstrate better quality of remission in schizophrenia patients treated with one- monthly and three-monthly paliperidone palmitate formulations, due to higher effi in preventing relapses, better safety and good tolerability regardless of patient age.
本文讨论了使用棕榈酸帕利哌酮治疗的病例报告，并与近期出版物中的数据进行了比较。第二代长效注射用抗精神病药物已被证明能更好地控制精神症状，减轻阴性症状的严重程度，改善患者及其亲属的社会功能和生活质量，并减轻医疗系统和护理人员的疾病负担。本文所呈现的病例报告表明，无论患者年龄如何，使用每月一次和每三个月一次的棕榈酸帕利哌酮制剂治疗的精神分裂症患者，由于预防复发的效率更高、安全性更好且耐受性良好，因此缓解质量更高。
